奥氮平暴露对伴精神病性特征抑郁症复发及脑结构的影响
本研究基于STOP-PD II随机安慰剂对照试验,分析舍曲林联合奥氮平达缓解后继续用药或换安慰剂36周的患者,发现奥氮平剂量与复发率及左皮质厚度变化相关,稳态浓度与左皮质厚度变化相关,但限定于奥氮平治疗者后关联不再显著。
要点
- 奥氮平剂量与复发率显著相关(N=118;HR=0.94,95%CI[0.897,0.977],p=0.002)。
- 奥氮平剂量与左皮质厚度变化相关(N=44;B=-2.0×10-3,95%CI[-3.1×10-3,-9.6×10-4],p<0.001)。
- 限定奥氮平治疗者后,剂量及稳态浓度与复发或皮质厚度的关联不再显著。
核心结论
- 在治疗范围内,奥氮平对复发或皮质厚度的影响不取决于剂量或稳态浓度。
研究设计与样本
- 基于STOP-PD II随机安慰剂对照试验,伴精神病性特征抑郁症患者经舍曲林联合奥氮平达缓解后随机继续舍曲林加奥氮平或安慰剂36周。
主要发现
- 奥氮平剂量与复发率显著相关(N=118;HR=0.94,95%CI[0.897,0.977],p=0.002)。
- 奥氮平剂量与左皮质厚度变化显著相关(N=44;B=-2.0×10-3,95%CI[-3.1×10-3,-9.6×10-4],p<0.001)。
- 奥氮平稳态浓度与左皮质厚度变化显著相关(N=44;B=-8.7×10-4,95%CI[-1.4×10-3,-3.6×10-4],p=0.001)。
- 右皮质发现类似结果。
- 限定于奥氮平治疗者后上述关联不再显著。
临床怎么用
- 临床决策中不应仅依据奥氮平剂量或稳态浓度预判复发风险或脑结构变化。
局限性
- 限定于奥氮平治疗者后关联不再显著,提示结果可能受组间比较影响。
- 需进一步研究奥氮平及其他抗精神病药对心境症状和脑结构的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Some data suggest that antipsychotics may adversely affect brain structure. We examined the relationship among olanzapine exposure, relapse, and changes in brain structure in patients with major depressive disorder with psychotic features. We analyzed data from the Study of the Pharmacotherapy of Psychotic Depression II trial (STOP-PD II), a randomized, placebo-controlled trial in patients with psychotic depression who attained remission on sertraline and olanzapine and were randomized to continue sertraline plus olanzapine or placebo for 36 weeks. Olanzapine steady state concentration (SSC) were calculated based on sparsely-sampled levels. Rates of relapse and changes in brain structure were assessed as outcomes. There were significant associations between dosage and relapse rates (N = 118; HR = 0.94, 95% CI [0.897, 0.977], p = 0.002) or changes in left cortical thickness (N = 44; B = -2.0 × 10-3, 95% CI [-3.1 × 10-3, -9.6 × 10-4], p < 0.001) and between SSC and changes in left cortical thickness (N = 44; B = -8.7 × 10-4, 95% CI [-1.4 × 10-3, -3.6 × 10-4], p = 0.001). Similar results were found for the right cortex. These associations were no longer significant when the analysis was restricted to participants treated with olanzapine. Our findings suggest that, within its therapeutic range, the effect of olanzapine on relapse or cortical thickness does not depend on its dosage or SSC. Further research is needed on the effect of olanzapine and other antipsychotics on mood symptoms and brain structure.
引用
- Kim HK, Voineskos AN, Neufeld NH, et al. Effect of olanzapine exposure on relapse and brain structure in patients with major depressive disorder with psychotic features. Mol Psychiatry. 2024. PMID: 38503927. doi:10.1038/s41380-024-02523-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。